DEA Cannabis Rescheduling Hearings: Timeline, Process & Impact

Executive Summary

The Drug Enforcement Administration's administrative hearings on cannabis rescheduling represent the most consequential federal drug policy proceeding in half a century, yet key stakeholder voices remain absent from the formal process. Following the Department of Health and Human Services' August 2023 recommendation to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, the DEA initiated a notice-and-comment rulemaking that has drawn over 43,000 public submissions. The agency announced in early 2026 that it would convene formal evidentiary hearings under 21 C.F.R. § 1316.41, marking the first time since 1988 that cannabis scheduling has proceeded to the Administrative Law Judge stage. However, the hearing participant list published in June 2026 excludes patient advocacy organizations, state regulatory officials, and small cannabis operators—groups representing millions of Americans directly affected by the outcome. The hearings, scheduled to begin in September 2026, will determine whether cannabis meets the five-factor analysis required under 21 U.S.C. § 811(c), with implications for $30 billion in annual cannabis sales, Section 280E tax burdens, medical research access, and the legal status of 42 state-legal programs.

Why This Matters

The DEA rescheduling hearings will shape the legal and economic landscape for 55 million American cannabis consumers, 15,000 licensed businesses, and hundreds of thousands of patients who rely on medical marijuana. The stakes extend across multiple domains. For patients, rescheduling to Schedule III would maintain federal prohibition while potentially expanding research access under protocols governed by the Food and Drug Administration and the National Institute on Drug Abuse. For businesses, the change would eliminate Internal Revenue Code Section 280E restrictions that currently prevent cannabis operators from deducting ordinary business expenses, potentially saving the industry $3 billion annually in federal tax liability according to 2024 estimates from the Marijuana Policy Project. State programs face uncertainty as well. While 24 states have legalized adult-use cannabis and 38 permit medical use, all operate in technical violation of the Controlled Substances Act. Schedule III status would not resolve this conflict—cannabis would remain federally prohibited for non-FDA-approved uses—but could influence Department of Justice enforcement priorities and banking access under the Bank Secrecy Act. The hearings also carry international implications under the Single Convention on Narcotic Drugs of 1961, to which the United States is a signatory. Any scheduling change requires notification to the United Nations Commission on Narcotic Drugs and potentially impacts trade relationships with treaty partners.

Background and History: Five Decades of Scheduling Battles

Cannabis has been trapped in Schedule I—the most restrictive category reserved for drugs with "no currently accepted medical use"—since the Controlled Substances Act took effect on May 1, 1971.

The Original Scheduling (1970-1971)

When Congress passed the Controlled Substances Act as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, cannabis was temporarily placed in Schedule I pending completion of the National Commission on Marihuana and Drug Abuse study. The commission, chaired by former Pennsylvania Governor Raymond Shafer, recommended decriminalization in its March 1972 report "Marihuana: A Signal of Misunderstanding." The Nixon administration rejected the recommendation, and cannabis remained in Schedule I.

The NORML Petition Era (1972-1992)

The National Organization for the Reform of Marijuana Laws filed the first rescheduling petition in May 1972, initiating a 22-year administrative battle. After years of DEA delays, Administrative Law Judge Francis Young held extensive hearings from 1986 to 1988, hearing testimony from physicians, patients, and researchers. In his September 6, 1988 opinion, Judge Young concluded that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man" and recommended rescheduling to Schedule II. DEA Administrator John Lawn rejected the recommendation in December 1989, a decision upheld by the D.C. Circuit Court of Appeals in Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131 (D.C. Cir. 1994).

The Medical Marijuana Movement (1996-2012)

California voters approved Proposition 215 in November 1996, establishing the nation's first medical cannabis program despite federal prohibition. The DEA responded with raids on state-compliant providers, leading to United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001), in which the Supreme Court ruled that medical necessity is not a defense to Controlled Substances Act violations. By 2012, 18 states had enacted medical cannabis laws, and Colorado and Washington became the first states to legalize adult use.

The Cole Memo and Enforcement Détente (2013-2018)

Deputy Attorney General James Cole issued guidance on August 29, 2013, instructing federal prosecutors to deprioritize enforcement in states with "strong and effective regulatory and enforcement systems." This policy, known as the Cole Memo, created a quasi-legal framework for state programs. Attorney General Jeff Sessions rescinded the memo on January 4, 2018, though practical enforcement patterns changed little.

The Biden Administration Directive (2022)

On October 6, 2022, President Joe Biden issued a statement directing Secretary of Health and Human Services Xavier Becerra and Attorney General Merrick Garland to "review expeditiously how marijuana is scheduled under federal law." This marked the first time a sitting president had formally called for rescheduling review.

The HHS Recommendation (2023)

Following a comprehensive review by the Food and Drug Administration, HHS delivered its recommendation to the DEA in August 2023. The recommendation, partially disclosed through Freedom of Information Act litigation, concluded that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances, supporting rescheduling to Schedule III alongside drugs like ketamine and anabolic steroids.

The Notice of Proposed Rulemaking (2024-2025)

The DEA published its Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, opening a 60-day comment period later extended to September 30, 2024. The docket received 43,233 submissions, including detailed comments from the American Medical Association, the National Cannabis Industry Association, 19 state attorneys general supporting rescheduling, and 14 state attorneys general opposing it. The DEA announced on December 12, 2025, that it would convene formal evidentiary hearings, appointing Administrative Law Judge Paul Soeffing to preside.

The Hearing Announcement (2026)

On March 18, 2026, the DEA published the hearing schedule and procedures in the Federal Register. The agency granted participant status to 17 entities, including the DEA itself, the Department of Health and Human Services, Smart Approaches to Marijuana, the American Society of Addiction Medicine, and several multi-state cannabis operators. Notably absent were Americans for Safe Access, the Drug Policy Alliance, the Minority Cannabis Business Association, and state regulatory officials from California, Colorado, and Washington—the three largest legal markets.

Key Players in the Rescheduling Process

The DEA rescheduling proceeding involves federal agencies with statutory authority, industry stakeholders with billions at stake, and advocacy organizations representing divergent policy positions.

Drug Enforcement Administration

The DEA holds final scheduling authority under 21 U.S.C. § 811(a), though it must request a scientific and medical evaluation from HHS before initiating proceedings. Administrator Anne Milgram, appointed in June 2021, has maintained public neutrality on rescheduling while emphasizing the agency's obligation to follow the Administrative Procedure Act's notice-and-comment requirements. The DEA's Diversion Control Division manages the scheduling process, while the Office of Chief Counsel provides legal analysis.

Department of Health and Human Services

HHS, through the FDA, conducted the eight-factor analysis required under the Controlled Substances Act. The analysis examined cannabis's abuse potential, scientific evidence of pharmacological effect, current scientific knowledge, history and pattern of abuse, scope and significance of abuse, risk to public health, psychic or physiological dependence liability, and whether the substance is an immediate precursor of a controlled substance. FDA's Center for Drug Evaluation and Research led the review, with input from the National Institute on Drug Abuse.

Multi-State Operators

Large cannabis companies including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings filed detailed comments supporting rescheduling, emphasizing Section 280E relief and banking access. These MSOs collectively operate over 500 dispensaries across more than 20 states and reported combined revenue exceeding $8 billion in 2025. Their participation in the hearings reflects the industry's maturation and its capacity to fund sophisticated regulatory advocacy.

Smart Approaches to Marijuana

SAM, founded by former Representative Patrick Kennedy and Kevin Sabet, leads opposition to rescheduling. The organization argues that cannabis meets Schedule I criteria due to its abuse potential and lack of FDA-approved formulations in botanical form. SAM submitted a 247-page comment citing international treaty obligations, public health concerns, and the availability of FDA-approved synthetic cannabinoids like dronabinol.

Medical and Scientific Organizations

The American Medical Association, representing over 250,000 physicians, supported rescheduling in its August 2024 comment, stating that Schedule I status "is not accurate, given the scientific evidence regarding marijuana's safety and efficacy in some clinical conditions." The American Society of Addiction Medicine took the opposite position, warning that rescheduling could increase access without adequate safeguards. The American Academy of Pediatrics expressed concerns about youth access and potency.

State Attorneys General

Nineteen attorneys general, led by New York's Letitia James and California's Rob Bonta, filed a joint comment supporting rescheduling and arguing that the current schedule creates untenable conflicts between state and federal law. Fourteen attorneys general, led by Nebraska's Mike Hilgers, opposed rescheduling, citing concerns about impaired driving, youth use, and interstate diversion.

Patient Advocacy Organizations

Americans for Safe Access, representing over 100,000 medical cannabis patients, sought participant status but was denied by the DEA. The organization argues that Schedule III status is insufficient because it maintains prohibition for non-FDA-approved uses, leaving patients in state programs without federal protection. The Epilepsy Foundation and Veterans Action Council similarly sought participation to present patient testimony.

Legal and Regulatory Framework

Cannabis rescheduling operates within a complex statutory structure established by the Controlled Substances Act, constrained by international treaty obligations, and subject to Administrative Procedure Act requirements. The Controlled Substances Act, codified at 21 U.S.C. §§ 801-971, establishes five schedules based on abuse potential, accepted medical use, and safety. Schedule I includes drugs with "high potential for abuse," "no currently accepted medical use in treatment in the United States," and lack of "accepted safety for use under medical supervision." Schedule III includes drugs with "potential for abuse less than the drugs or other substances in schedules I and II," "currently accepted medical use in treatment in the United States," and abuse that "may lead to moderate or low physical dependence or high psychological dependence." The scheduling process requires an eight-factor analysis under 21 U.S.C. § 811(c): actual or relative potential for abuse; scientific evidence of pharmacological effect; state of current scientific knowledge; history and current pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance already controlled. The Administrative Procedure Act, 5 U.S.C. §§ 551-559, governs the rulemaking process. The DEA must provide notice, accept public comments, and respond to significant issues raised. When the agency receives requests for a hearing from interested parties, it must convene a formal evidentiary proceeding under 21 C.F.R. § 1316.41. The Administrative Law Judge's recommended decision is subject to review by the DEA Administrator, whose final order is reviewable by federal courts of appeals under the substantial evidence standard. International obligations complicate domestic rescheduling. The Single Convention on Narcotic Drugs of 1961 requires parties to maintain controls on cannabis consistent with Schedule I or Schedule IV of the Convention's schedules. The United States argued in its 2020 notification regarding CBD that domestic scheduling changes do not violate treaty obligations if adequate controls remain in place. However, Schedule III placement could face scrutiny from the International Narcotics Control Board. Section 280E of the Internal Revenue Code, enacted in 1982, prohibits businesses from deducting ordinary expenses if they traffic in Schedule I or II substances. The provision has generated substantial litigation, including Olive v. Commissioner, 139 T.C. 19 (2012), which held that separate business lines may deduct expenses unrelated to cannabis sales. Rescheduling to Schedule III would eliminate 280E's application, fundamentally altering cannabis business economics.

State-by-State Legal Status

Forty-two states have legalized cannabis for medical or adult use, creating a patchwork of regulatory regimes that would remain in technical federal violation even under Schedule III.

California

California operates the nation's largest cannabis market, with $5.3 billion in legal sales in 2025. The state legalized medical use through Proposition 215 in 1996 and adult use through Proposition 64 in 2016. The Department of Cannabis Control licenses cultivators, manufacturers, distributors, retailers, and testing laboratories. Possession limits are 28.5 grams of flower and 8 grams of concentrate for adults 21 and older. Rescheduling would not change state law but could influence banking access and interstate commerce discussions.

Colorado

Colorado's adult-use program, established by Amendment 64 in 2012, generated $1.8 billion in sales in 2025. The Marijuana Enforcement Division within the Department of Revenue oversees licensing. Possession limits are one ounce of flower and 8 grams of concentrate. Colorado has expressed interest in interstate commerce compacts if federal prohibition ends, but Schedule III status would not authorize such arrangements.

New York

New York legalized adult use through the Marijuana Regulation and Taxation Act in March 2021. The Office of Cannabis Management issued its first adult-use retail licenses in November 2022. The state projects $1.3 billion in annual sales by 2027. Possession limits are three ounces of flower and 24 grams of concentrate. New York's social equity licensing program prioritizes applicants from communities disproportionately impacted by prohibition.

Florida

Florida operates a medical-only program established by Amendment 2 in 2016, with over 800,000 registered patients as of 2026. The state does not permit adult use, and a November 2024 ballot initiative to legalize recreational cannabis failed with 57% support, short of the 60% threshold required for constitutional amendments. Rescheduling could influence future ballot efforts by reducing federal-state conflict concerns.

Texas

Texas maintains one of the nation's most restrictive medical programs, limited to patients with epilepsy, seizure disorders, multiple sclerosis, spasticity, amyotrophic lateral sclerosis, autism, terminal cancer, and incurable neurodegenerative diseases. THC content is capped at 1% by weight. Possession of any amount of cannabis outside the medical program remains a criminal offense. Texas has not indicated whether rescheduling would influence state policy.

Ohio

Ohio voters approved adult-use legalization through Issue 2 in November 2023, with sales beginning in August 2024. The Division of Cannabis Control within the Department of Commerce oversees licensing. Possession limits are 2.5 ounces of flower. Ohio's program includes automatic expungement provisions for prior cannabis convictions, affecting an estimated 400,000 residents.

Pennsylvania

Pennsylvania operates a medical program established in 2016, with over 450,000 registered patients. The state does not permit adult use, though Governor Josh Shapiro has expressed support for legalization. Rescheduling could influence legislative debates by reducing concerns about federal preemption and banking access.

Market and Business Implications

Rescheduling to Schedule III would eliminate the Section 280E tax burden, potentially saving cannabis businesses $3 billion annually, but would not resolve fundamental conflicts between state and federal law. The most immediate impact would be tax relief. Cannabis operators currently pay effective federal tax rates exceeding 70% in some cases due to the inability to deduct rent, payroll, marketing, and other ordinary expenses. Rescheduling would allow standard business deductions under Internal Revenue Code Section 162, dramatically improving profitability. Publicly traded MSOs have indicated they would redirect tax savings toward expansion, research and development, and price reductions to compete with illicit markets. Banking access could improve marginally. The Bank Secrecy Act requires financial institutions to file Suspicious Activity Reports for transactions involving proceeds from illegal activity. While Schedule III cannabis would remain federally prohibited for non-FDA-approved uses, some banks may interpret the rescheduling as a signal of reduced enforcement risk. However, comprehensive banking reform likely requires legislation such as the SAFER Banking Act, which passed the House in 2023 but stalled in the Senate. Capital markets could see increased institutional investment. Many pension funds, mutual funds, and institutional investors maintain policies prohibiting investment in companies that violate federal law. Rescheduling might not fully resolve these concerns, but the reduced schedule could influence investment committee decisions. Cannabis-focused exchange-traded funds reported $800 million in assets under management as of 2026, a figure that could grow substantially with broader institutional participation. Interstate commerce would remain prohibited. Schedule III substances may only be distributed by DEA-registered entities for FDA-approved uses. State-legal cannabis programs would continue to operate in violation of federal law, preventing the interstate shipments that could reduce costs and improve efficiency. Some industry analysts estimate that interstate commerce could reduce wholesale prices by 30-40% through economies of scale. Research access could expand significantly. Currently, researchers studying cannabis must obtain approval from the DEA, FDA, and National Institute on Drug Abuse, and source material from a limited number of federally approved cultivators. Schedule III status would simplify DEA registration requirements and potentially expand the number of approved research cultivators, accelerating clinical trials for conditions including chronic pain, PTSD, and chemotherapy-induced nausea.

What Experts Say

Medical professionals, economists, and legal scholars offer divergent assessments of rescheduling's likely impacts, with disagreement centered on public health effects and the adequacy of Schedule III as a policy solution. According to Dr. Bertha Madras, a Harvard Medical School psychobiology professor who served on the President's Commission on Combating Drug Addiction, rescheduling could send a misleading message about cannabis safety. In her August 2024 comment to the DEA, Madras argued that "the scientific evidence does not support the conclusion that marijuana has a currently accepted medical use" in botanical form, as opposed to FDA-approved synthetic cannabinoids. Dr. Jahan Marcu, a pharmacologist and former chief scientist at Americans for Safe Access, took the opposite view in testimony before the House Oversight Committee in March 2024. Marcu stated that "the preponderance of evidence demonstrates cannabis has accepted medical use for multiple conditions" and that Schedule I status "impedes research that could lead to better understanding of dosing, drug interactions, and long-term effects." Economists project substantial market impacts. Beau Whitney, senior economist at Whitney Economics, estimated in a January 2026 report that Section 280E relief could reduce retail cannabis prices by 15-20% as operators pass savings to consumers. However, Whitney cautioned that "price reductions could increase consumption among heavy users and youth if not accompanied by strong regulatory controls." Legal scholars debate whether rescheduling would survive judicial review. Professor Robert Mikos of Vanderbilt Law School argued in a 2024 law review article that the DEA's analysis must address the conflict between HHS's conclusion that cannabis has accepted medical use and the fact that no FDA-approved botanical cannabis products exist. Mikos suggested that courts could find the rescheduling arbitrary and capricious under the Administrative Procedure Act if the DEA does not adequately explain this tension. State regulators have expressed concerns about implementation. Andrew Freedman, former director of marijuana coordination for Colorado, said in a June 2024 interview that "Schedule III creates a regulatory no-man's land where state programs continue to operate outside federal law, but without the clarity of Schedule I's bright-line prohibition."

What's Next: Timeline and Decision Points

The DEA rescheduling hearings will unfold over six to nine months, with a final decision unlikely before mid-2027 and potential litigation extending the process into 2028. The evidentiary hearings are scheduled to begin on September 8, 2026, in Arlington, Virginia. Administrative Law Judge Paul Soeffing will hear testimony from the 17 approved participants over an estimated 15-20 hearing days. Each participant may present witnesses, cross-examine opposing witnesses, and submit documentary evidence. The DEA has indicated that hearings will address the eight-factor analysis, international treaty obligations, and potential implementation challenges. Following the close of evidence, participants will submit proposed findings of fact and conclusions of law by December 15, 2026. Judge Soeffing will issue a recommended decision by March 31, 2027. The recommendation is not binding; DEA Administrator Milgram will review the record and issue a final order, likely by June 30, 2027. Any final order will face immediate litigation. Parties opposing rescheduling would file petitions for review in federal courts of appeals, likely the D.C. Circuit, within 60 days of publication in the Federal Register. Parties supporting rescheduling might also sue if they believe the DEA's decision is insufficiently protective of state programs or patient access. Litigation could take 12-18 months, potentially reaching the Supreme Court if circuit courts split on key issues. If rescheduling proceeds, the Internal Revenue Service would need to issue guidance on Section 280E's termination. The IRS has indicated it would provide a transition period for tax year 2027 or 2028, allowing businesses to adjust accounting systems. State tax authorities in the 32 states that conform to federal tax law would need to decide whether to maintain separate cannabis tax provisions. Congressional action remains possible. Senator Cory Booker and Representative Nancy Mace have introduced legislation to deschedule cannabis entirely, removing it from the Controlled Substances Act. While comprehensive reform faces long odds in a divided Congress, rescheduling could build momentum for incremental changes such as banking reform or research expansion. International implications will unfold over years. The United States would need to notify the United Nations Commission on Narcotic Drugs of any scheduling change. Treaty partners including Canada, which legalized cannabis in 2018, and Mexico, which legalized in 2021, would likely support the U.S. position. However, countries including Russia, China, and several Middle Eastern nations could object, potentially triggering diplomatic discussions about treaty interpretation.

Further Reading and Primary Sources

• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (Federal Register, May 21, 2024): https://www.federalregister.gov/documents/2024/05/21/2024-10006/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to DEA on Cannabis Scheduling (August 2023, released via FOIA): https://www.hhs.gov/about/agencies/ash/marijuana-scheduling-recommendation
• Controlled Substances Act, 21 U.S.C. §§ 801-971: https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• Administrative Procedure Act, 5 U.S.C. §§ 551-559: https://www.law.cornell.edu/uscode/text/5/part-I/chapter-5
• DEA Hearing Procedures, 21 C.F.R. § 1316.41: https://www.ecfr.gov/current/title-21/chapter-II/part-1316
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• Single Convention on Narcotic Drugs (1961): https://www.unodc.org/unodc/en/treaties/single-convention.html
• Judge Francis Young's 1988 Recommended Decision (DEA Docket No. 86-22): https://www.druglibrary.org/schaffer/hemp/medical/young1.htm
• President Biden's October 6, 2022 Statement on Cannabis Policy: https://www.whitehouse.gov/briefing-room/statements-releases/2022/10/06/statement-from-president-biden-on-marijuana-reform
• American Medical Association Comment on Cannabis Rescheduling (August 2024): https://www.ama-assn.org/delivering-care/public-health/ama-supports-rescheduling-marijuana
• Smart Approaches to Marijuana Comment on Cannabis Rescheduling (September 2024): https://learnaboutsam.org/dea-comment-2024
• National Cannabis Industry Association Economic Impact Report (2025): https://thecannabisindustry.org/economic-impact-2025
• Congressional Research Service Report on Cannabis Scheduling (Updated January 2026): https://crsreports.congress.gov/product/pdf/LSB/LSB10655